持続的腎代替療法 (CRRT)の世界市場...市場調査レポートについてご紹介

1 Introduction (Page No. – 16)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 20)
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
2.2.1.1 Key Data From Secondary Sources
2.2.2 Primary Research
2.2.2.1 Key Data From Primary Sources
2.2.2.2 Key Industry Insights
2.3 Market Size Estimation Methodology
2.4 Market Data Validation and Triangulation
2.5 Assumptions for the Study

3 Executive Summary (Page No. – 32)

4 Premium Insights (Page No. – 37)
4.1 Market Potential
4.2 Market Opportunity
4.3 CRRT Market, By Product and Modality (2015 vs 2020)
4.4 CRRT Market, By Modality (2015)
4.5 CRRT Market, By Country (2015 vs 2020)

5 Market Overview (Page No. – 41)
5.1 Introduction
5.2 Market Segmentation
5.2.1 By Product
5.2.2 By Modality
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Increasing Prevalence of AKI
5.3.1.2 Rising Adoption of CRRT for the Treatment of Renal Disorders
5.3.1.3 Growing Number of Icu Patients
5.3.1.4 Rapid Rise in Aging Population
5.3.1.5 Clinical Advantages of CRRT Over Intermittent Blood Purification Techniques
5.3.1.6 CRRT is A Gold Standard for Treatment of Hemodynamically Unstable Patients
5.3.1.7 Technological Advancements and New Product Launches
5.3.1.8 Increasing Prevalence of Sepsis
5.3.2 Restraints
5.3.2.1 High Complexity of Therapy
5.3.2.1.1 Lack of Standard Treatment Guidelines
5.3.2.1.2 Complications Associated With CRRT
5.3.2.2 High Procedural Cost of CRRT
5.3.2.3 Stringent Regulatory Guidelines for CRRT in North America
5.3.2.4 Dearth of Trained Icu Nurses
5.3.3 Opportunities
5.3.3.1 Emerging Markets
5.3.3.2 Broadening Application Horizon of CRRT
5.3.3.2.1 Evolution of CRRT From Simple Renal Replacement Treatment to A Multi-Organ Support Therapy (Most)
5.3.3.2.2 CRRT: Progression From Adaptive Renal Devices to Multipurpose Treatment Machines
5.3.3.3 Ongoing Researches to Establish Safety and Efficacy Profile of CRRT
5.3.3.4 Development of A CRRT System for Pediatric Patients
5.3.3.4.1 the Carpediem Project
5.3.3.5 Untapped Market Growth Opportunities in North America
5.3.4 Challenges
5.3.4.1 Poor Reimbursement Scenario in Developing Countries
5.3.4.2 Lack of Substantial Clinical Evidences Supporting Efficacy of CRRT
5.3.4.3 Currently Approved CRRT Technology is Inadequate for Children
5.3.4.4 Lack of Awareness About the Benefits of CRRT
5.3.5 Winning Imperatives
5.3.5.1 Selling Machines Along With Disposables to End Users.
5.3.5.2 High Bargaining Margins on Disposables as Well as Machines
5.3.5.3 Development of CRRT Machine That is Only Compatible With Respective Company’s Disposables
5.3.5.4 Core Competency of Players
5.3.6 Industry Trends
5.3.6.1 Training Programs for the Operation of CRRT Devices
5.3.6.2 Rising Adoption of User-Friendly CRRT Machines

6 Industry Insights (Page No. – 59)
6.1 Introduction
6.2 Reimbursement Scenario
6.2.1 North America
6.2.2 Europe
6.2.3 Asia-Pacific (Excluding Japan)
6.2.4 Japan
6.2.5 Rest of the World
6.3 Regulatory Landscape
6.3.1 North America
6.3.2 Europe
6.3.3 Asia-Pacific
6.3.4 Rest of the World
6.4 Porter’s Five Forces Analysis
6.4.1 Competitive Intensity
6.4.2 Bargaining Power of Buyers
6.4.3 Bargaining Power of Suppliers
6.4.4 Threat of Substitutes
6.4.5 Threat of New Entrants
6.5 Pricing and Cost Analysis
6.6 Strategic Recommendations
6.6.1 Design Recommendations for CRRT Machines
6.6.2 Key Strategies for Players Seeking to Enter the CRRT Market

7 Adoption of CRRT, By Region (Page No. – 70)
7.1 Introduction
7.2 Utilization of CRRT Procedures, By Region
7.3 Number of CRRT Patients, By Region

8 CRRT Market, By Product (Page No. – 74)
8.1 Introduction
8.1.1 Dialysate and Replacement Fluids
8.1.2 CRRT Disposables
8.1.2.1 Hemofilters
8.1.2.2 Bloodline Sets (Tubing Sets)
8.1.2.3 Other Disposables
8.1.3 CRRT Systems

9 CRRT Market, By Modality (Page No. – 85)
9.1 Introduction
9.2 Continuous Venovenous Hemofiltration (CVVH)
9.3 Continuous Venovenous Hemodiafiltration (CVVHDF)
9.4 Continuous Venovenous Hemodialysis (CVVHD)
9.5 Slow-Continuous Ultrafiltration (SCUF)

10 CRRT Market, By Region (Page No. – 96)
10.1 Introduction
10.2 CRRT Market, By Region
10.2.1 Europe
10.2.1.1 CRRT Machines Approved for Multiple Applications
10.2.1.2 Intensivists’ Preference for CRRT for AKI Treatment
10.2.1.3 Players Focus on Leveraging Growth Opportunities in Europe
10.2.1.4 Germany
10.2.1.4.1 Rising Focus of Players on the German CRRT Market
10.2.1.5 U.K.
10.2.1.5.1 Rising Awareness About AKI in U.K.
10.2.1.6 France
10.2.1.6.1 Symposia and Conferences
10.2.1.7 Rest of Europe
10.2.1.7.1 Clinical Research and Trials Driving Market Growth in Roe
10.2.2 North America
10.2.2.1 North American Utilization of CRRT Lower Than That of Europe, Australia, and Japan
10.2.2.2 Regulatory Policies, A Key Hindrance to Market Growth
10.2.2.3 U.S.
10.2.2.3.1 Prevalence of AKI, Esrd Rising Due to Growth in Aging Population
10.2.2.3.2 Technological Advancement to Boost Demand for CRRT Products
10.2.2.3.3 Ongoing Clinical Trials to Prove Safety and Efficacy of CRRT Products
10.2.2.3.4 Government Funding & Grants to Develop Cost-Effective Treatments for AKI Patients
10.2.2.3.5 Shortage of Registered Nurses in Icu Settings
10.2.2.4 Canada
10.2.2.4.1 Rising AKI Prevalence
10.2.2.4.2 Barriers to Enter the Canadian CRRT Market
10.2.2.4.3 High Costs of CRRT as Compared to Ihd
10.2.3 Asia-Pacific
10.2.3.1 High Use of CRRT in Australia and Japan
10.2.3.2 Studies and Clinical Trials to Establish the Safety and Efficacy Profile of CRRT
10.2.3.3 Dearth of Reimbursement and Technical Expertise
10.2.3.4 Japan
10.2.3.4.1 Japan Focusing on the Use of CRRT for Non-Renal Indications
10.2.3.4.2 Large Number of Domestic Manufacturers – A Barrier to the Entry of Major Players
10.2.3.5 China
10.2.3.5.1 Rising Incidence of AKI and Esrd in the China
10.2.3.6 India
10.2.3.7 Rest of Asia-Pacific
10.2.3.7.1 High Utilization of CRRT in Australia
10.2.4 Rest of the World (RoW)
10.2.4.1 South Africa
10.2.4.2 Latin America and the Middle East

11 Competitive Intelligence Analysis (Page No. – 131)
11.1 Competitive Intensity
11.1.1 Evaluation Parameters and Scores
11.1.2 Scoring Methodology
11.1.3 Competitive Intensity Score, By Company
11.1.3.1 Baxter International Inc.
11.1.3.2 Nxstage Medical, Inc.
11.1.3.3 B. Braun Melsungen AG
11.1.3.4 Fresenius Medical Care AG & Co. KGAA
11.1.4 Competitive Intensity – Mapping of Baxter, Nxstage, B.Braun, and Fresenius
11.1.5 Market Share Analysis
11.1.5.1 Baxter International Inc.
11.1.5.2 Fresenius Medical Care AG & Co. KGAA
11.1.5.3 Nxstage Medical, Inc.
11.2 Competitive Situation and Trends
11.2.1 Product Approvals, Launches, and Enhancements
11.2.2 Expansions
11.2.3 Acquisitions
11.2.4 Agreements, Partnerships, and Collaborations

12 Company Profiles (Page No. – 144)
(Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, MnM View)*
12.1 Introduction
12.2 Baxter International Inc.
12.3 Fresenius Medical Care AG & Co. KGAA
12.4 Nikkiso Co., Ltd.
12.5 B. Braun Melsungen AG
12.6 Nxstage Medical, Inc.
12.7 Asahi Kasei Medical Co., Ltd. (A Subsidiary of Asahi Kasei Corporation)
12.8 Bellco S.R.L.
12.9 Infomed SA
12.10 Medica S.P.A
12.11 Medical Components, Inc.
12.12 Toray Medical Company Limited

*Details on Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, MnM View Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. – 165)
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.3 Introducing RT: Real-Time Market Intelligence
13.4 Available Customizations
13.5 Related Reports